| __timestamp | Ionis Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 241751000 | 14400000 |
| Thursday, January 1, 2015 | 322292000 | 33800000 |
| Friday, January 1, 2016 | 344320000 | 35900000 |
| Sunday, January 1, 2017 | 374644000 | 1254000 |
| Monday, January 1, 2018 | 1820000 | 4889000 |
| Tuesday, January 1, 2019 | 4000000 | 7400000 |
| Wednesday, January 1, 2020 | 12000000 | 10100000 |
| Friday, January 1, 2021 | 11000000 | 14300000 |
| Saturday, January 1, 2022 | 14000000 | 23200000 |
| Sunday, January 1, 2023 | 9133000 | 39700000 |
| Monday, January 1, 2024 | 11215000 | 34000000 |
Data in motion
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for two prominent players: Neurocrine Biosciences, Inc. and Ionis Pharmaceuticals, Inc., from 2014 to 2023.
Ionis Pharmaceuticals, Inc. experienced a significant fluctuation in its cost of revenue, peaking in 2017 with a staggering 374 million, before plummeting to just 1% of that in 2018. This dramatic shift highlights the volatile nature of the biotech industry. In contrast, Neurocrine Biosciences, Inc. demonstrated a more consistent upward trajectory, with a notable 175% increase from 2014 to 2023, reaching nearly 40 million.
These trends underscore the strategic differences in cost management between the two companies, offering valuable insights for those keen on the financial health and operational strategies of biotech firms.
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Ionis Pharmaceuticals, Inc.
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Ionis Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Viatris Inc. vs Ionis Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and HUTCHMED (China) Limited
Comparing Cost of Revenue Efficiency: Ionis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored